Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Background and Purpose—There are limited real-world data comparing the effectiveness
and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians …

Background and Purpose—Limited evidence exists on the effectiveness and safety of
warfarin and all 4 available non-vitamin K antagonist oral anticoagulants (NOACs) from …

Background Although randomized trials provide a high level of evidence regarding the
efficacy of non-vitamin K oral anticoagulants (NOACs), the results of such trials may differ …

Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …

Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone
treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived …

Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as
alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for …

Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …